Una guía para la práctica | 11 AGO 19

Retención urinaria por obstrucción prostática benigna

Revisión sistemática y un metaanálisis sobre el manejo de esta patología masculina tan pevaalente en hombres mayores
6
9
Autor: Markos Karavitakis, Iason Kyriazis , Muhammad Imran Omar y col. EUR URO-8261 May 2019 Volume 75, Issue 5,
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

[1] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminol-ogy of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–78.

 [2] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminol-ogy in lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Urology 2003;61:37–49.

[3] Kaplan SA, Wein AJ, Staskin DR, Roehrborn CG, Steers WD. Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol 2008;180:47–54.

[4] Oelke M, Speakman MJ, Desgrandchamps F, Mamoulakis C. Acute urinary retention rates in the general male population and in adult men with lower urinary tract symptoms participating in pharma-cotherapy trials: a literature review. Urology 2015;86:654–65.

[5] Verhamme KM, Dieleman JP, van Wijk MA, Bosch JL, Stricker BH, Sturkenboom MC. Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 2005;47:494–8.

[6] Agrawal MS, Yadav A, Yadav H, Singh AK, Lavania P, Jaiman R. A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary reten- tion caused by benign prostatic hyperplasia. Indian J Urol 2009;25:474–8.

[7] McNeill SA, Daruwala PD, Mitchell ID, Shearer MG, Hargreave TB. Sustained-releasealfuzosinandtrialwithoutcatheterafteracuteurinary retention: a prospective, placebo-controlled. BJU Int 1999;84:622–7.

[8] Shah T, Palit V, Biyani S, Elmasry Y, Puri R, Flannigan GM. Random-ised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. Eur Urol 2002;42:329–32.

[9] Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the manage-ment of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 2005;95:354–7.

[10] Kumar S, Tiwari DP, Ganesamoni R, Singh SK. Prospective random-ized placebo-controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology 2013;82:171–5.

[11] McNeill SA, Hargreave TB. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. J Urol 2004;171:2316–20.

[12] Taube M, Gajraj H. Trial without catheter following acute retention of urine. Br J Urol 1989;63:180–2.

ç[13] Breum L, Klarskov P, Munck LK, Nielsen TH, Nordestgaard AG. Significance of acute urinary retention due to intravesical obstruc-tion. Scand J Urol Nephrol 1982;16:21–4.

[14] Michel MC, Goepel M. Lower urinary tract symptoms suggestive of benign prostatic obstruction-what's the long-term effectiveness of medical therapies? Eur Urol 2001;39(Suppl. 3):20–5.

[15] Kuiper JG, Bezemer ID, Driessen MT, et al. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride. BMC Urol 2016;16:53

 [16] Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123–31.

[17] Pickard R, Emberton M, Neal DE. The management of men with acute urinary retention National Prostatectomy Audit Steering Group. Br J Urol 1998;81:712–20.

18] Warren JW. Catheter-associated urinary tract infections. Infect Dis Clin North Am 1997;11:609–22.

19] Brasure M, Fink HA, Risk M, et al. Chronic urinary retention: comparative effectiveness and harms of treatments. Rockville, MD: Agency for Healthcare Research and Quality; 2014.

[20] Fisher E, Subramonian K, Omar MI. The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men. Cochrane Database Syst Rev 2014;6:Cd006744.

[21] Yoon PD, Chalasani V, Woo HH. Systematic review and meta-anal-ysis on management of acute urinary retention. Prostate Cancer Prostat Dis 2015;18:297–302.

[22] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–13.

[23] Mamoulakis C, Efthimiou I, Kazoulis S, Christoulakis I, Sofras F. The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostate. World J Urol 2011;29:205–10.

[24] Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401–6.

[25] Moher DL, Liberty A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.

[26] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.

[27] Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, Version 5.1.0 (updated March 2011). The Cochrane. www.handbook.cochrane.org.

[28] Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol 2011;64:1294–302.

[29] Knoll T, Omar MI, Maclennan S, et al. Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology. Eur Urol 2018;73:290–300.

[30] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring incon-sistency in meta-analyses. BMJ 2003;327:557–60.

[31] Al-Hashimi MMR. Alfuzosin 10 mg once daily in the management of acute urinary retention of benign prostatic hyperplasia: a double-blind, placebo-controlled study. Curr Urol 2007;1:28–34.

[32] Hassan S, El-Ebiary M, Mabrouk M. Early versus late trail of catheter removal in patients with urinary retention secondary to benign prostatic hyperplasia under tamsulosin treatment. Urol Sci 2018;29:288–92.

[33] Kara O, Yazici M. Is the double dose alpha-blocker treatment super- ior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperpla- sia? Urol J 2014;11:1673–7.

[34] Maldonado-Avila M, Manzanilla-Garcia HA, Sierra-Ramirez JA, et al. A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter re-moval in patients with benign prostatic growth. Int Urol Nephrol 2014;46:687–90.

[35] Patil SB, Ranka K, Kundargi VS, Guru N. Comparison of tamsulosin and silodosin in the management of acute urinary retention sec-ondary to benign prostatic hyperplasia in patients planned for trial without catheter. A prospective randomized study. Cent Eur J Urol 2017;70:259–63.

[36] Prieto L, Romero J, Lopez C, Ortiz M, Pacheco JJ. Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urol Int 2008;81:66–71.

[37] Sharifi SH, Mokarrar MH, Khaledi F, Yamini-Sharif R, Lashay A, Soltani MH. Does sildenafil enhance the effect of tamsulosin in relieving acute urinary retention? Int Braz J Urol 2014;40:373–8.

[38] Tiong HY, Tibung MJ, Macalalag M, Li MK, Consigliere D. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urol Int 2009;83:44–8.

[39] Ghalayini IF, Al-Ghazo MA, Pickard RS. A prospective randomized trial comparing transurethral prostatic resection and clean inter- mittent self-catheterization in men with chronic urinary retention. BJU Int 2005;96:93–7.

[40] Mamoulakis C, Schulze M, Skolarikos A, et al. Midterm results from an international multicentre randomised controlled trial compar- ing bipolar with monopolar transurethral resection of the prostate. Eur Urol 2013;63:667–76.

[41] Schelin S, Geertsen U, Walter S, et al. Feedback microwave thermo-therapy versus TURP/prostate enucleation surgery in patients with benign prostatic hyperplasia and persistent urinary retention: a prospective, randomized, controlled, multicenter study. Urology 2006;68:795–9.

[42] Zhengyong Y, Changxiao H, Shibing Y, Caiwen W. Randomized controlled trial on the efficacy of bladder training before removing the indwelling urinary catheter in patients with acute urinary retention associated with benign prostatic hyperplasia. Scand J Urol 2014;48:400–4.

[43] Guazzoni G, Montorsi F, Bergamaschi F, Consonni P, Bellinzoni P, Rigatti P. Prostatic spiral versus prostatic Urolume wallstent for urinary retention due to benign prostatic hyperplasia. A long-term comparative study. Eur Urol 1993;24:332–6.

[44] Horgan AF, Prasad B, Waldron DJ, O'Sullivan DC. Acute urinary retention. Comparison of suprapubic and urethral catheterisation. Br J Urol 1992;70:149–51.

[45] Patel MI, Watts W, Grant A. The optimal form of urinary drainage after acute retention of urine. BJU Int 2001;88:26–9.

[46] Mamoulakis C, Skolarikos A, Schulze M, et al. Results from an international multicentre double-blind randomized controlled trial on the perioperative efficacy and safety of bipolar vs monopolar transurethral resection of the prostate. BJU Int 2012;109:240–8.

[47] Mamoulakis C, Skolarikos A, Schulze M, et al. Bipolar vs monopolar transurethral resection of the prostate: evaluation of the impact on overall sexual function in an international randomized controlled trial setting. BJU Int 2013;112:109–20.

[48] Cetti RJ, Hicks JA, Venn SN, Carter PG, Britton JP. Results from an international multicentre double-blind randomized controlled trial on the perioperative efficacy and safety of bipolar vs monopolar transurethral resection of the prostate. BJU Int 2012;109:E38–40, [author reply].

[49] KiddEA, Stewart F, KassisNC, HomE,Omar MI. Urethral(indwellingor intermittent) or suprapubic routes for short-term catheterisation in hospitalised adults. Cochrane Database Syst Rev 2015;12:CD004203

50] Gravas S, Cornu JN, Drake MJ, et al. Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO)Presented at the EAU Annual Congress Copenhagen 2018. Arnhem, The Netherlands: EAU Guide-lines Office; 2018.978-94-92671-01-1 In: http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí